Exelixis Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Los beneficios de Exelixis han disminuido a una tasa media anual de -30.8%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 17% al año. La rentabilidad financiera de Exelixis es de 9.2%, y sus márgenes netos son de 11.4%.

Información clave

-30.8%

Tasa de crecimiento de los beneficios

-32.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	17.0%
Rentabilidad financiera	9.2%
Margen neto	11.4%
Próxima actualización de resultados	30 Apr 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30

Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise

Oct 18

Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs

Jul 07

Exelixis: Becoming A Giant Pharma

May 18

Exelixis: Beyond The Cabozantinib Franchise

Apr 21

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Exelixis. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:EXEL Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	1,830	208	543	1,044
30 Sep 23	1,774	92	531	1,136
30 Jun 23	1,714	164	507	1,002
31 Mar 23	1,664	154	488	969
31 Dec 22	1,611	182	460	892
30 Sep 22	1,638	308	440	777
30 Jun 22	1,555	273	426	742
31 Mar 22	1,521	298	402	691
31 Dec 21	1,435	231	402	694
30 Sep 21	1,254	164	385	626
30 Jun 21	1,157	94	371	639
31 Mar 21	1,031	65	333	605
31 Dec 20	988	112	293	548
30 Sep 20	958	152	269	488
30 Jun 20	998	282	232	409
31 Mar 20	979	294	231	376
31 Dec 19	968	321	228	337
30 Sep 19	956	612	223	300
30 Jun 19	910	642	219	247
31 Mar 19	856	650	212	208
31 Dec 18	854	690	206	182
30 Sep 18	745	368	200	157
30 Jun 18	672	323	190	141
31 Mar 18	585	253	179	127
31 Dec 17	452	154	159	112
30 Sep 17	410	150	126	104
30 Jun 17	320	58	120	95
31 Mar 17	257	6	116	90
31 Dec 16	191	-70	116	96
30 Sep 16	124	-147	120	96
30 Jun 16	71	-181	106	101
31 Mar 16	43	-186	83	103
31 Dec 15	37	-162	57	96
30 Sep 15	35	-178	50	113
30 Jun 15	31	-195	42	130
31 Mar 15	30	-229	46	157
31 Dec 14	25	-261	51	189
30 Sep 14	22	-281	55	199
30 Jun 14	21	-286	58	203
31 Mar 14	27	-275	55	201
31 Dec 13	31	-245	51	179
30 Sep 13	35	-226	47	162
30 Jun 13	43	-192	41	145

Ingresos de calidad: EXEL tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (11.4%) de EXEL son superiores a los del año pasado (11.3%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de EXEL han disminuido en un 30.8% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de EXEL en el último año (14%) supera su media de 5 años (-30.8% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de EXEL en el último año (14%) superó al de la industria Biotechs -8.9%.

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de EXEL (9.2%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Exelixis Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Recent updates

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Independent Director notifies of intention to sell stock

Executive Vice President of Commercial recently sold US$1.0m worth of stock

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2023 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Executive VP notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Consensus EPS estimates fall by 10%

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CEO, President & Director exercised options and sold US$2.1m worth of stock

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

New major risk - Revenue and earnings growth

Executive Vice President of Commercial recently sold US$632k worth of stock

Consensus EPS estimates increase by 11%

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Executive VP notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Insider notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma

Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Consensus EPS estimates fall by 15%

Executive Vice President of Commercial notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023

CEO, President & Director exercised options and sold US$816k worth of stock

Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Exelixis, Inc. Provides Revenue Guidance for Full Year 2023

Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

Insider exercised options and sold US$234k worth of stock

Exelixis, Inc. Announces Board Appointments

Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Independent Director notifies of intention to sell stock

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Exelixis, Inc. Provides Revenue Guidance for 2022

Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise

Executive Vice President of Commercial notifies of intention to sell stock

Exelixis: Efforts Continue To Diversify The Pipeline

Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

Desglose de ingresos y gastos
Beta